The global antibody drug conjugates market is estimated at USD 7.01 Bn in 2025 and is expected to grow at a compound annual growth rate (CAGR) of 14.2% from 2025 to 2032, reaching USD 17.76 Bn by 2032.
|
Current Event |
Description and its Impact |
|
Regulatory Framework Evolution and Accelerated Approvals |
|
|
Breakthrough Technological Innovations in ADC Development |
|
|
Healthcare Infrastructure and Market Access Evolution |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Artificial Intelligence (AI) is playing an important role in the development of antibody drug conjugates (ADCs). It helps researchers identify the best antibodies and drugs to combine, predict how they will behave in the body, and optimize their design for better effectiveness and safety.
AI also speeds up the discovery process, reduces costs, and improves decision-making in clinical trials. It is making ADC development faster, smarter, and more efficient. As a result, antibody drug conjugate manufacturers are increasingly embracing this advanced technology.
For instance, in January 2025, Lantern Pharma launched its AI-powered RADR module. This new AI-powered tool is designed to make developing antibody-drug conjugates (ADCs) for cancer faster, cheaper, and more precise.
Adcetris segment is expected to hold a dominant share of 40.8% in the global antibody drug conjugates market revenue in 2025. This is mainly because it is widely accepted by doctors and patients for treating various cancers. Its proven effectiveness and broad use make it the most popular choice compared to other ADCs.
Adcetris is being widely used to treat certain type of lymphoma, including relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). As a result, it is witnessing increased approval across various regions.
For instance, in June 2025, European Commission approved ADCETRIS® (brentuximab vedotin) for the treatment of adult patients with newly diagnosed stage IIb/III/IV Hodgkin Lymphoma in combination with ECADD. These approvals will further improve share of the target segment during the forthcoming period.
Based on application, breast cancer segment is anticipated to dominate the global antibody drug conjugates industry during the assessment period. This is attributable to increasing prevalence of breast cancer.
Breast cancer is one of the most common cancers globally. According to the International Agency for Research on Cancer (IARC), there will be about 3.2 million new breast cancer cases by 2050 if the current trends continue.
This high prevalence is expected to create a strong demand for effective treatments, including antibody drug conjugates, during the forthcoming period. ADCs are known for targeting cancer cells more precisely while reducing damage to healthy tissues.
Development of several FDA-approved ADCs specifically for breast cancer treatment is also boosting the target segment. These therapies have shown promising results in improving patient outcomes, especially for aggressive or hard-to-treat breast cancers.
To learn more about this report, Download Free Sample
North America is expected to dominate the global ADCs market, capturing a share of 37.7% in 2025. This can be attributed to increasing prevalence of cancer, advancements in ADC technology, strong regulatory support, and new product launches or approvals.
The U.S. Food and Drug Administration (FDA) is continuously approving novel therapies like ADCs to tackle the burden of cancer. For instance, in June 2025, FDA approved Datroway (datopotamab deruxtecan-dlnk) for advanced non-small cell lung cancer. These approvals reflect the region's commitment to expanding treatment options for various cancer types.
Europe remains the second-largest market for antibody drug conjugates, and the trend will likely continue during the assessment period. This growth can be attributed to increased investment in cancer research, advanced healthcare infrastructure, and adoption of innovative therapies across the region.
Nations like Germany, the U.K., and France are leading in funding clinical trials and supporting biotechnology companies working on ADCs. For example, Germany is investing heavily in next-generation cancer treatments, which is expected to boost demand for ADCs in hospitals and research centers.
Leading manufacturers of antibody drug conjugates are expanding their presence across European nations to capitalize on emerging opportunities. For instance, in May 2025, BioNTech announced plans to invest up to £1 billion over the next decade to expand its research and development activities in the UK. This investment will help the company bring innovative cancer treatment to market.
The United States remains a key market for antibody drug conjugates. This is mainly due to rising cancer patient pool, strong investment in cancer research, and advanced biotechnology. Increasing government funding and private investment in clinical trials support the development of innovative ADC therapies.
Major pharmaceutical companies, including Pfizer, Seattle Genetics, and Amgen, are actively working on new ADC candidates and expanding their production capabilities. For example, Seattle Genetics recently announced progress in its late-stage ADC pipeline, which is expected to enhance treatment options for multiple cancer types.
Adoption of cutting-edge technologies, such as site-specific conjugation and improved linker technologies, is helping U.S. companies maintain a competitive edge as well as meet growing patient demand. Similarly, rising interest in personalized medicine is driving demand for antibody drug conjugates in the nation.
China continues to see rapid growth in the ADC market, fueled by increasing domestic manufacturing capabilities and expanding healthcare infrastructure. The country is focused on boosting local production of ADCs to reduce dependency on imports and improve access to innovative cancer therapies.
Local biotech firms such as Hengrui Medicine, Chi-Med, and Innovent Biologics are leading ADC development in China. They often collaborate with global partners for technology transfer and clinical development.
For instance, Innovent Biologics advanced a novel ADC into late-stage clinical trials, highlighting the country’s growing capacity to develop and commercialize complex therapies. Government support for biotech innovation and faster regulatory approvals is expected to sustain strong market growth.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 7.01 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 14.2% | 2032 Value Projection: | USD 17.76 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical Company Ltd |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The global incidence of cancer is increasing at an alarming pace across nations like China, India, and the United States. For example, American Cancer Society estimates that there will be about 2,041,910 new cancer cases and 618,120 cancer deaths in the U.S. in 2025.
This surge in cancer cases is boosting demand for antibody drug conjugates (ADCs) and other therapies. ADCs are emerging as powerful tools against the rising cancer burden. They combine the targeting ability of monoclonal antibodies with the strong cancer-killing effect of cytotoxic drugs to eradicate cancer cells.
One of the major factors hampering market growth is unavoidable toxic side effects, which are caused by the premature release of cytotoxic small molecules into the bloodstream. According to an article published by Biopharma PEG, a biotechnology-oriented company, most existing ADCs appear to have a toxicity profile dominated by "off-target, off-tumor" events.
The associated increased risk is determined by the toxicity profile of cytotoxic small molecules. Maytansine (DM1) off-target toxicity included hepatotoxicity and thrombocytopenia. Monomethyl auristatin E (MMAE) was linked to an increased risk of peripheral neuropathy, neutropenia, and anemia.
The compound monomethyl auristatin F (MMAF) has been linked to ocular toxicity. Key players operating in this market need to develop innovative ADCs that are less toxic than existing ones, which will assist in creating lucrative opportunities for market development over the forecast period.
ADC have gained significant traction in recent years, and more players are entering the market; however, some lack financial capital to develop their robust pipeline of ADC. This has encouraged startups to raise funds through financing round; such initiatives are anticipated to support the development of the ADC market over the projected period.
For instance, in April 2023, Novo Holdings A/S, a leading international life sciences investor, announced a new investment in Alentis Therapeutics AG, a clinical-stage biotechnology company, of USD105 million in Series C financing. The company is developing breakthrough treatments for organ fibrosis and Claudin-1 (CLDN1)-positive tumors.
The funding will be used to support the clinical development of Alentis' lead investigational products, ALE.F02 and ALE.C04, as well as the development of the CLDN1 platform. CLDN1 antibody drug conjugates (ADC) and bi-specific antibodies are being engineered using the platform.
Share
Share
About Author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
